同位素2011，Vol.24Issue(z1)：68-75,8.
整合素素αVβ3受体显像剂18F标记RGD肽的研究进展
Advance of 18F Labeled RGD Peptide as Integrin αVβ3 Receptor Imaging Agents
摘要
Abstract
Angiogenesis is vital for tumor growth and metastasis. Integrin αv β3 receptor has been shown to play a key role in tumor angiogenesis and metastasis. The highly expression of integrin αv β3 receptor in endothelial cells and tumor cells presents an interesting molecular target for diagnosis and treatment of the rapidly growing and metastatic tumors. Argi-nine-glycine-aspartic acid ( Arg-Gly-Asp, RGD) peptide can specifically target to integrin αv β3 receptor. 18F labeled RGD peptides can be used to non-invasively visualize and quantify αvβ3 integrin expression levels, and play a key role in early diagnosis of tumor, monitoring and evaluation of anti-angiogenesis. In recent years, there has been a great acceleration in the development of radiolabeled receptor-binding peptides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging in nuclear on-cology. Integrin αvβ3 receptor is expected to become the new target spot of radioactive substance, while the radioactive nuclide labeled RGD peptides will be a potential tumor imaging agent in clinical. This article reviews the recent development of 18F labeled RGD peptide and its application in tumor integrin αvβ3 receptor imaging.关键词
18F标记RGD肽/整合素αVβ3/受体显像剂/研究进展Key words
18F labeled RGD peptide/integrin αvβ3/ receptor imaging agents/advance分类
医药卫生引用本文复制引用
王立振,杨敏..整合素素αVβ3受体显像剂18F标记RGD肽的研究进展[J].同位素,2011,24(z1):68-75,8.基金项目
国家自然科学基金资助项目(81101077,81171399) （81101077,81171399）
